Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial

This publication has 23 references indexed in Scilit:

• Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction
  Journal of the American College of Cardiology, 2002
• Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes
  Circulation, 2001
• The Continuing Epidemics of Obesity and Diabetes in the United States
  JAMA, 2001
• Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study
  European Heart Journal, 2000
• Abciximab Facilitates the Rate and Extent of Thrombolysis
  Circulation, 1999
• Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
  New England Journal of Medicine, 1998
• Shear-Induced Platelet Adhesion and Aggregation on Subendothelium Are Increased in Diabetic Patients
  Thrombosis Research, 1998
• Platelet-Leukocyte-Cross-Talk in Diabetes Mellitus
  Hormone and Metabolic Research, 1997
• Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.
  Journal of the American College of Cardiology, 1997
• Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus
  New England Journal of Medicine, 1990